📰 Expanded Access Program News
Page 9 - Expanded Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Expanded Access Program. Real-time updates on events, politics, business and more.
April 6, 2023
Operator: Greetings, and welcome to the Brainstorm Cell Therapeutics Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode.
April 4, 2023
- The Expanded Access Program is funded by a grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS for ALS patients who... | April 4, 2023
April 3, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed...
April 3, 2023
RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,500,000 of the Company's American...
March 30, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...
March 30, 2023
Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and...
March 27, 2023
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, today reported...
March 24, 2023
EQS-News: Heidelberg Pharma AG / Key word: Annual Report Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business 24.03.2023 / 07:11... | March 24, 2023
March 16, 2023
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it plans to...
March 15, 2023
/PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company developing less invasive therapies to directly treat the dilated left ventricle...